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Familial adenomatous polyposis (FAP) is an autosomal dominantly inherited disorder, which
results from a germ line mutation in the APC (adenomatous polyposis coli) gene. FAP is
characterized by the formation of hundreds to thousands of colorectal adenomatous polyps.
Although the development of colorectal cancer stands out as the most prevalent complication,
FAP is a multisystem disorder of growth. This means, it is comparable to other diseases such
as the MEN syndromes, Von Hippel-Lindau disease and neuroﬁbromatosis. However, the
incidence of many of its clinical features is much lower. Therefore, a specialized multidisci-
plinary approach to optimize health care—common for other disorders—is not usually taken
for FAP patients. Thus, clinicians that care for and counsel members of high-risk families
should have familiarity with all the extra-intestinal manifestations of this syndrome. FAP-
related complications, for which medical attention is essential, are not rare and their estimated
lifetime risk presumably exceeds 30%. Affected individuals can develop thyroid and pancre-
atic cancer, hepatoblastomas, CNS tumors (especially medulloblastomas), and various benign
tumors such as adrenal adenomas, osteomas, desmoid tumors and dental abnormalities. Due
to improved longevity, as a result of better prevention of colorectal cancer, the risk of these
clinical problems will further increase.We present a clinical overview of extra-intestinal
manifestations, including management and treatment options for the FAP syndrome. Fur-
thermore, we provide recommendations for surveillance of FAP complications based on
available literature.
Key Words: Familial adenomatous polyposis—Extra-intestinal manifestations—Multisystem
disorder.
In the early 1950s, Gardner described that in some
patients hereditary polyposis could occur simulta-
neously with multiple cutaneous and subcutaneous
lesions and osteomatosis.
1 Initially, the triad of extra-
intestinal manifestations composed of soft tissue
cysts, osteomas and dental abnormalities was referred
to as Gardner syndrome. This terminology is now
used only from a historical point of view. Indeed,
retrospective research proved that extra-intestinal
tumors could be found in almost all families with
familial adenomatous polyposis (FAP), if the affected
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2439patients were examined carefully.
2 FAP is not
uncommon with an incidence reported to vary from
1:6,850 to 1:23,700 live births
3–5 and leads to devel-
opment of colorectal carcinoma in almost 100% of
cases by 40 years of age. The introduction and work
of (national) polyposis registries and prophylactic
colectomy has greatly improved life expectancy for
patients with FAP.
6,7
Surveillance recommendations for the prevention of
other intestinal malignancies, such as duodenal ampul-
lary carcinomas and gastric carcinomas, have been
issued and are widely implemented.
8–11 In contrast, less
attention has been given to the diverse extra-intestinal
features of FAP. Clinical awareness of health problems
that are (seemingly) not related to intestinal manifesta-
tions is necessary because improved life expectancy in
FAP patients has increased their prevalence.
In this paper, we review the extra-intestinal mani-
festations of FAP. To facilitate risk assessment of
identiﬁed adenomatous polyposis coli (APC) gene
mutations, a guideline of well-established genotype–
phenotype correlations is provided (Fig. 1). In addi-
tion, recommendations for surveillance are given for
extra-intestinal malignancies (Table 1) and benign
manifestations (Table 2). The commonly used
GRADE criteria were used to describe both the
strength of recommendations (1–4) and the quality of
evidence (A–D).
MOLECULAR GENETICS
The APC gene located on 5q21–22 is mutated in
FAP. Most mutations will result in stop codons and
lead to truncation of the APC gene product. These
mutations have a nearly complete penetrance of the
colonic phenotype, but a variable penetrance of
extra-colonic manifestations of the disease. Modifier
genes, variable interference of different mutant APC
proteins on the wild-type APC function and envi-
ronmental factors may play a role in extra-intestinal
tumor formation.
12
The APC protein is a large scaﬀolding protein with
several functions.
13 It is involved in the Wnt signaling
cascade. As part of a multiprotein complex, the APC
protein downregulates b-catenin activity.
14 In the
absence of a Wnt signal, APC forms a complex with
the protein b-catenin, allowing it to be targeted for
destruction. When APC function is lost, b-catenin
accumulates in the cytoplasm and binds to several
transcription factors of the TCF/LEF, thereby
altering the expression of various genes affecting
proliferation, differentiation, migration and apopto-
sis of cells.
13 In addition, APC stabilizes microtu-
bules, leading to chromosomal stability.
15,16
Inactivation of APC can lead to defective chromo-
some segregation and aberrant mitosis.
17
FAP AND THYROID CARCINOMA
Epidemiology and Genetics
Thyroid cancer in a patient with FAP was ﬁrst
described in 1949 by Crail.
18 Almost 40 years later,
Plail and coworkers reviewed 998 patients with FAP
and found that thyroid carcinoma occurred more
frequent in FAP patients than in the general popu-
FIG. 1. Genotype–phenotype correlations of extra-intestinal familial adenomatous polyposis (FAP) manifestations according to the available
literature.
21,39,109,111 The APC gene consists of 15 exons. The highest cumulative frequencies of extra-colonic manifestations are found
between codons 976–1,067 and 1,310–2,011. The margins of codon regions associated with extra-intestinal manifestations are not absolute and
merely provide a guideline. No genotype–phenotype correlations have been established for pancreatic carcinoma, brain tumors or adrenal
gland adenomas. CHRPE congenital hypertrophy of the retinal pigment epithelium.
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19 The largest FAP registries have reported a
life time risk of 1–2%,
19,20 but some consider this an
underestimation.
21 There is a striking female pre-
ponderance (female to male ratio 17:1). The average
age at diagnosis is 27 years. It has never been found
to present before 15 years of age.
22 Young women
(less than 35 years of age) are at particular risk of
developing thyroid cancer, and their chances of being
affected are approximately 160 times that of normal
individuals.
19 Familial clustering has been described
several times.
23 A strong association with Congenital
Hyperplasia of the Retinal Pigment Epithelium
(CHRPE, see below) exists—since most of the
mutations cluster in the genomic area, characteristic
of both extra-colonic manifestations. Genetic analy-
sis most often shows a mutation in exon 15, in the 5’
portion of the APC gene outside the Mutational
Cluster Region (i.e., before codon 1,220).
Clinical Findings
Papillary thyroid carcinoma (PTC) almost invari-
ably presents as a node in the thyroid gland. Other
thyroid carcinomas have been described but are very
rare. Fine needle aspiration biopsy (FNAB) of the
node will establish the diagnosis, but sometimes a
diagnostic hemithyroidectomy is necessary. The his-
tological pattern typically shows a cribriform (mor-
ular) papillary thyroid carcinoma, but this is not
entirely speciﬁc. Although multifocality in the thyroid
gland and regional lymph node involvement often
occur, FAP-associated PTC is a relatively indolent
tumor. Treatment of PTC initially consists of total
thyroidectomy and administration of radioiodine
(131-I), followed by TSH suppression therapy. As a
group, the prognosis is very favorable, with recur-
rence-free patient survival of more than 15 years.
21,23
After proper treatment, patients with no distant
metastases are likely to have a normal residual life-
span.
24,25
Considerations for Surveillance
Thyroid surveillance in patients with FAP syn-
drome is recommended due to the known increased
risk of thyroid cancer in this group and the ease and
TABLE 1. Recommendations for surveillance of malignant extra-intestinal manifestations of familial adenomatous polyposis
Manifestation
Population
at risk
a
Lifetime
prevalence
Recommendation
for surveillance Additional diagnostic considerations
Papillary thyroid
carcinoma
Women, 15–35 years
Concomitant CHRPE
Family history of
thyroid carcinoma
1–2% Look for palpable nodules
at least yearly and refer
to endocrinologist for
FNAB if present
Level 3, B: Sigurdson
26
Optionally: perform ultrasonography
of thyroid gland every 1–2 years and
refer if nodules present are larger
than 10 mm or larger than 5 mm
with characteristics associated
with malignancy
b
Level 3, B: Papini
29
Hepatoblastoma Boys, 0–4 years, but
may present up to
16 years
Family history
of hepatoblastoma
1–2% Serial measurement of aFP
Abdominal ultrasound
Suspicious hepatic lesions:
CT or MRI
Surveillance should
commence within the ﬁrst
month after birth and
continued every 3 months
at least up to the age
of 4 years
38
Level 4, D: Thomas,
36
Aretz,
38 Sanders
43
Brain tumor Medulloblastoma:
5–38 years
Other brain tumors:
22–80 years
Family history
of brain tumor
1–2% Surveillance not
recommended
Level 4, D: this article
Awareness of signs and symptoms
related to CNS tumors
Pancreatic
cancer
>±30 years 1% Surveillance not
recommended
Level 4, D: this article
Awareness of signs and symptoms
related to pancreatic cancer
Pay attention to the pancreas
at CT or MRI
CHRPE congenital hypertrophy of the retinal pigment epithelium, FNAB ﬁne needle aspiration biopsy.
a Supplementary to those deﬁned by codon mutation (as depicted in Fig. 1).
b Hypoechogenic nodules, irregular margins, hypervascularity or microcalciﬁcations.
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dations are comparable to those for populations at
high-risk of thyroid cancer, such as childhood cancer
survivors who received radiotherapy to the head,
neck or upper region.
26 Although no speciﬁc proto-
cols are available, physical examination of the neck
and thyroid gland can be advocated.
26 FNA—in case
of suspected nodules—is recommended.
27,28 The use
of (color Doppler) ultrasonography for thyroid gland
examination is still controversial, but makes it pos-
sible to analyze non-palpable thyroid nodules and
assess potentially malignant characteristics.
29
FAP AND HEPATOBLASTOMAS
Epidemiology and Genetics
Hepatoblastoma is an embryonal neoplasm com-
posed of malignant epithelial tissue with variable
diﬀerentiation, most often with embryonal or fetal
components. The tumor predominantly occurs in
children between 6 months and 3 years of age, but
the age at diagnosis can range from prenatal stages to
16 years. The clinical association between hepato-
blastoma and FAP was ﬁrst reported by Kingston
et al. in 1983,
30 and more than 50 cases have now
been reported.
31 However, hepatoblastomas are also
related to several other genetic abnormalities and
malformation syndromes, the most important of
which are Beckwith-Wiedemann syndrome, trisomy
18, fetal alcohol syndrome and extreme premature
birth.
32 The risk of hepatoblastoma is 750–7,500
times higher in children from FAP families than in
the general population.
33,34 This higher incidence
contributed signiﬁcantly to the observed increased
cancer mortality in the age group between 1 and
4 years in a Japanese polyposis registry;
35 however,
the absolute risk for hepatoblastoma in children with
FAP is less than 2%.
33 Familial clustering of hepat-
oblastomas has been described several times (re-
viewed by Thomas et al.
36). The age at diagnosis and
the increased incidence in boys is similar between
FAP- and non-FAP-related hepatoblastomas.
37
Mutation analysis revealed that almost 95% of the
mutations were on the 5’ to mid region of the APC
gene between codons 141 and 1,751.
37,38 However, it
is generally accepted that the site of the APC muta-
tion cannot be used to predict the occurrence of
hepatoblastoma.
39 Because FAP and hepatoblastoma
are rare, the precise epidemiological relationship be-
tween these diseases has been difﬁcult to quantify.
Clinical Findings
Hepatoblastoma presents as an abdominal mass.
While often asymptomatic in early stages, patients
typically present with constipation, abdominal pain,
TABLE 2. Recommendations for surveillance of benign extra-intestinal manifestation of familial adenomatous polyposis
Manifestation Population at risk
a
Lifetime
prevalence
Recommendation
for surveillance
Additional diagnostic
considerations
Adrenal tumors >14 years 7–13% Surveillance not recommended
Refer to endocrinologist if
adrenal adenoma is present
at CT or MRI
Level 4, D this article
Adrenal adenomas can produce cortisol,
aldosterone, androgens or catecholamines
Pay attention to signs or symptoms related
to excess of these hormones (e.g., moon-
face, striae, hypertension, hirsutism)
Diagnostic work-up according
to NIH Guideline
81
Desmoid tumors Peak incidence±30 years
After surgery
(median time±2 years)
Family history
of desmoid tumors
Presence of osteomas
20% Surveillance not recommended
Level 4, D: this article
Evaluate palpable abdominal
masses or symptoms related to
abdominal organ obstruction
Optionally: consider CT
or MRI scan
Level 3, C: Healy
95
Osteomas Presence of CHRPE
or desmoids
Positive family history
of osteomas
20% Surveillance not recommended
Level 4, D this article
Pay attention to mandibula problems.
Refer to dental surgeon if osteomas
cause problems. Various bone
localizations are possible
Dental
abnormalities
Children/during dental
development
17% Refer to dentist or dental surgeon
Serial OPG every 1–2 years
Level 4, D: Wijn,
101 this article
CHRPE congenital hypertrophy of the retinal pigment epithelium, OPG orthopantomography (panorex).
a Supplementary to those deﬁned by codon mutation (as depicted in Fig. 1).
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advanced tumors. The diagnosis is conﬁrmed by an
elevated a-fetoprotein (aFP) in approximately 90%
of cases, by liver imaging and, ultimately, by biop-
sy.
40 Survival is highly related to the success of
complete tumor resection.
38 Preoperative chemo-
therapy (usually consisting of cisplatin and doxoru-
bicin) is very helpful and many previously irresectable
tumors can become completely amenable to surgery.
Although the combination of chemotherapy and
surgery is very successful, an estimated 25% of all
patients do not survive this disease.
38,41
Considerations for Surveillance
There are no validated and generally accepted
guidelines of surveillance for hepatoblastoma in FAP
families. According to their recently published sur-
veillance protocol, Aretz et al. recommend analysis of
(changes in) serial aFP measurements and abdominal
ultrasound. Suspicious hepatic lesions on sonography
should be further investigated with CT or MRI.
Surveillance should commence within the ﬁrst month
after birth and continued every 3 months at least up
to the age of 4 years.
38 Due to limitations in the
interpretation of aFP as a marker for hepatoblas-
toma at a very young age or due to the lack of aFP
production in undifferentiated tumors, false-positive
or false-negative results can be obtained. When the
classical criteria of Wilson and Jungner are applied
for surveillance, it remains questionable whether the
diagnostic tests are suitable.
42 However, the disease is
more easily curable if detected at an early stage, and
several authors thus favor surveillance of young
children in FAP families.
36,38,43
FAP AND BRAIN TUMORS
Epidemiology and Genetics
In 1959, Turcot and colleagues described two
teenaged siblings with numerous adenomatous pol-
yps of the colorectum in whom malignant tumors of
the central nervous system (CNS) developed.
44 The
association of primary brain tumors and colorectal
polyposis has since been described in the literature
under the eponym ‘‘Turcot’s syndrome’’. The asso-
ciation between brain tumors and colorectal polyp-
osis has been renamed the ‘‘brain tumor–polyposis’’
(BTP) syndrome.
45 Both clinically
45 and molecu-
larly,
46 this appeared to be a heterogeneous disorder
with at least two clinical entities. The BTP syndrome
type 1 results from mutations in DNA mismatch re-
pair genes characteristic of Lynch syndrome or
hereditary non-polyposis colorectal cancer
(HNPCC). The brain tumors are usually high-grade
astrocytomas or glioblastomas.
45 It is also referred to
as ‘‘true Turcot’s syndrome’’. It should be noted that
the original description of Turcot is confusing, be-
cause what he described was most likely a HNPCC
case with (few) colon polyps. The BTP syndrome type
2 typically consists of a medulloblastoma associated
with colorectal polyposis in a patient who belongs to
a FAP family.
45 In the context of this review, we have
focused on FAP-associated brain tumors. The ter-
minology of BTP or Turcot’s syndrome is preferen-
tially used only from a historical point of view.
Medulloblastomas account for 80% of the brain
tumors found in FAP. However, high-grade astro-
cytomas and ependymomas have also been
described.
46 Medulloblastoma is a highly malignant
embryonal CNS tumor primarily affecting children in
the ﬁrst decade of life, and 70% occurs before the age
of 16 years. The relative lifetime risk of any brain
tumor among members from a FAP family is
increased by a factor 7, and that of medulloblastoma
by a factor 90. However, the absolute lifetime risk of
any brain tumor is approximately 1–2%.
46
Clinical Findings
Medulloblastoma generally occurs in the midline
cerebellum and, therefore, presents with signs or
symptoms of obstructive hydrocephalus and cere-
bellar dysfunction, usually over a period of weeks to
months. Typical symptoms are emesis, horizontal
diplopia, clumsiness or frank ataxia, and headaches.
Currently, patients with medulloblastoma are best
treated with surgical removal of the tumor, radiation
therapy and/or chemotherapy depending on age,
extent of resection and presence of metastases.
47 The
overall 5-year survival has risen to 50–70% in the
past decades. The median overall survival appeared
to be much longer among patients who present with
colon polyps first.
48 This observation has to be con-
ﬁrmed in other series of patients.
Considerations for Surveillance
There are a number of familial syndromes that
predispose individuals to CNS tumors; examples are
von Hippel-Lindau (VHL) disease and neuroﬁbro-
matosis type 1 (NF-1). The lifetime risk of CNS
hemangioblastomas in VHL is 60–80%. Improved
surveillance of patients at risk for VHL disease,
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the age of 11 years, has substantially improved
diagnosis and treatment.
49 Optic nerve gliomas are
seen in 15% of patients with NF-1. Patients with NF-
1 are usually seen by a multidisciplinary clinical team.
Cranial MRIs for the detection of these gliomas are
usually reserved for children with abnormalities
during their annual vision evaluation.
50 In contrast to
these familial syndromes, brain tumors in FAP fam-
ilies are associated with a much lower lifetime risk.
Furthermore, annual surveillance of asymptomatic
patients may not be often enough, since medullo-
blastoma is a highly malignant tumor that is usually
only symptomatic 6 months or less before diagnosis.
Therefore, surveillance by means of regular CT or
MRI cannot be advocated. However, members from
a FAP family who do not yet have polyposis, but do
have signs or symptoms suggestive of a brain tumor,
should be evaluated with neuro-imaging because
brain tumors present before the diagnosis of polyp-
osis in over half of the FAP patients.
46 Careful
evaluation is also important among FAP families in
which one member already has a brain tumor since
familial clustering occurs. Of such families with FAP-
associated brain tumors, 40% had two affected
members.
46 Doctors who care for members of FAP
families should be aware of the association with
medulloblastoma and, thus, increase their sensitivity
to signs or symptoms of CNS tumors. Additionally,
education of members of FAP families about extra-
colonic manifestations could be useful.
FAP AND PANCREATIC TUMORS
Epidemiology and Genetics
Pancreatic tumors in FAP patients are rare. In a
cohort study of 1,391 patients with FAP reported in
the Johns Hopkins Registry, 4 patients were found to
have developed a pancreatic adenocarcinoma.
51 Their
age ranged from 32 to 78 years. From this, a signiﬁ-
cantly higher relative risk [RR: 4.5 (95% conﬁdence
limits 1.2–11.4)] of pancreatic carcinoma was calcu-
lated in polyposis patients and their relatives than in
the general population. Few other types of pancreatic
malignancies have been described. Two cases of in-
traductal papillary-mucinous neoplasm,
52,53 one cys-
tic and papillary carcinoma,
54 one acinar cell
carcinoma
55 and two islet cell tumors
56,57 have been
reported in association with FAP. In addition, some
pancreatic premalignant lesions
58–60 and a pancreatic
cyst due to desmoid ﬁbromatosis in a 17-year-old
male
61 have been described. No evidence of familial
clustering is evident from the literature.
Clinical Findings
Pancreatic carcinomas are often clinically silent for
a long time. In more advanced stages, patients may
experience pain, weight loss, jaundice or diarrhea
(steatorrhea). Diabetes, pancreatitis and thrombo-
phlebitis also occur. The prognosis of adenocarcino-
mas of the pancreas is generally poor. Treatment
options consist of surgery and chemotherapy.
62
Considerations for Surveillance
In view of the low prevalence of pancreatic cancer
and the scarcity of published data, surveillance is not
routinely recommended. Future protocols may in-
clude MR imaging and endoscopic ultrasonography
(EUS).
63 The clinician should be aware that pancre-
atic neoplasia can develop. When abdominal imaging
is performed, for example in the evaluation of des-
moid tumors or adrenal gland adenomas, attention
should be given to potential abnormalities in the
pancreas.
FAP AND ADRENAL TUMORS
Epidemiology and Genetics
Adrenal adenomas are frequently occurring extra-
intestinal manifestations of FAP. The ﬁrst case of a
FAP patient with an adrenal adenoma was published
almost a century ago.
64 Since then, approximately 50
cases have been reported in the literature, many of
them being asymptomatic and discovered at au-
topsy.
65–76 Age ranges from 14 to 70 years, with a
median of approximately 40–50 years. As a result of
technological advances in imaging techniques such as
CT andMRIduringthe last decades, newinformation
has become available regarding the prevalence of
adrenal masses in both the general population and
patients with FAP. In a retrospective study, Marchesa
et al. found a 7% prevalence of so-called ‘‘inciden-
talomas’’ in FAP patients,
69 compared with approxi-
mately 3% in the general population.
77 Smith et al.
even showed a prevalence of adrenal masses of 13% in
aprospectivestudy.
74Familialclusteringhasalsobeen
described.
71 Although the prevalence of adrenal mas-
ses in FAP patients are two to four times as high as in
the general population, the clinical presentation, and
biological behavior do not seem to be different.
69,74
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although production of cortisol,
66,69,76 aldosterone
65
and their combination have been reported.
73 Smith
et al. described apatientwith apheochromocytoma.
74
Data on genetic analysis are limited, and only three
mutations have been described (codons 1,061, 1,542
and1,981).Thelatterwasassociatedwithmultipleand
bilateral adenomas.
68 Adrenal carcinomas in associa-
tion with FAP are very rare and only six have been
described.
69,70,72,78–80
Clinical Findings
Adrenal adenomas usually present as clinically
unapparent adrenal masses, detected incidentally
with imaging studies conducted for other reasons.
The two major clinical concerns are that adrenal
masses may overproduce hormones or that they
represent adrenal cortical carcinomas. By deﬁnition,
no clinical symptoms or signs of adrenal disease
should be present at the time of diagnosis in patients
with incidentally detected adrenal masses. However, a
more detailed questioning and a careful physical
examination might reveal subtle evidence for hor-
mone excess. Hormonal assessment is usually done
by an endocrinologist, in some countries also by an
endocrine surgeon. In addition, repeat imaging after
6–12 months is necessary to assess malignant poten-
tial. Clinically silent lesions that are less than 4 cm
are generally not resected. Surgery is indicated in
adrenal masses larger than 6 cm because they fre-
quently harbor malignancies and, in the case of
hormone-producing adenomas, because of the meta-
bolic consequences. For lesions between 4 and 6 cm,
with benign characteristics on imaging, that do not
appear to overproduce hormones, both close follow-
up and adrenalectomy are considered a reasonable
approach.
81
Considerations for Surveillance
Based on the low incidence of hormone-producing
adrenal adenomas and the rarity of adrenal cancer in
FAP patients, surveillance does not seem to be justi-
ﬁed. However, clinical awareness is very important.
Subtle clues such as weight gain, hypertension or
hypokalemia and diabetes mellitus may prompt fur-
ther hormonal analysis. Once a tumor in the adrenals
is identiﬁed, hormonal and radiological evaluations
according to the NIH conference guidelines need to be
performed.
81 Patients should be referred to an endo-
crinologist. This is especially important since recent
reports suggest that up to 20% of patients with
adrenal incidentaloma (which means 1–3% of all FAP
patients) have some form of subtle and subclinical
hormonal dysfunction resulting in an increased risk of
metabolic disorders and cardiovascular disease.
FAP AND DESMOID TUMORS
Epidemiology and Genetics
Desmoid tumors are a very important cause of
mortality in patients with FAP.
6 There is an
approximate 1000-fold increase of developing des-
moid tumors in FAP patients when compared to the
general population.
82 Desmoids can be found at any
age and have been documented from infancy to
81 years of age.
83 The most common age of presen-
tation is between 20 and 40 years, with a median age
of 30 years, as reviewed by Knudsen et al.
84 The risk
of such tumor formation is increased after prior
surgery. Jarvinen found that the median interval be-
tween the operation and the diagnosis of desmoid
was a little over 2 years.
85 The lifetime risk associated
with these tumors in a Finnish and Italian registry
was estimated to be approximately 21%.
86,87 The
most important risk factors are a positive family
history, presence of osteomas or epidermoid cysts
and an APC gene mutation between codons 1,444
and 1,578.
86
Clinical Findings
Most desmoid tumors in FAP patients arise in the
abdomen, most frequently intra-abdominally (in the
mesentery of the small bowel) but also in the
abdominal wall (some in surgical scars). Fewer than
10% are located outside the abdomen.
83,88,89
Depending on localization, desmoid tumors can be
either asymptomatic or cause pain and various gas-
trointestinal complaints. Mesenteric desmoids may
cause small bowel obstruction, ureter compression,
small intestinal ischemia, abscess formation, intesti-
nal perforation or ﬁstulas.
Desmoid tumors are poorly understood. They are
inﬁltrative and non-metastasizing, with a histologi-
cally benign appearance apart from the surrounding
tissue inﬁltration. Approximately 5–10% appear to
resolve spontaneously.
88,90 In addition, 30% undergo
cycles of progression and resolution, and 50% remain
stable after diagnosis. However, 10% progress rap-
idly, growing to massive sizes and inﬁltrating adja-
cent structures.
90 Treatment is indicated when they
cause symptoms, pose a great risk to adjacent struc-
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trolled trials on the treatment of desmoid tumors.
Furthermore, many studies of desmoids are con-
founded by inclusion of both FAP-associated and
sporadic disease, which may represent two biologi-
cally distinct entities.
91 Thus, treatment modalities
are not well established. For intra-abdominally
located tumors, treatment with sulindac (non-steroi-
dal anti-inﬂammatory drug) and/or a selective estro-
gen receptor modulator (tamoxifen/torimifene) is
advised as ﬁrst line therapy.
83,84,89 Cytotoxic che-
motherapy has been used for desmoids that are not
responsive to less aggressive therapies.
61,83,84 Surgery
is generally not recommended as ﬁrst-line therapy for
intra-abdominal desmoids because recurrence rate
and morbidity are reported to be extremely high,
including bleeding, short bowel and postoperative
death (8 of 22 patients in the series from St. Marks),
88
although a later report from the same group claimed
that it was less hazardous than previously reported.
92
In addition, it is commonly believed that resection
triggers growth and therefore recurrences. However,
when medical treatment of large mesenteric desmoids
fails, surgery remains a valuable option.
93
Surgery is indicated as ﬁrst line therapy for tumors
located in the abdominal wall and extra-abdomi-
nally.
88 For patients with positive resection margins,
adjuvant radiotherapy can be given.
94 Nevertheless, it
can be argued that abdominal wall desmoids need not
be resected, but can be observed as the natural history
is variable and recurrence after surgery is frequent.
Considerations for Surveillance
There is no consensus about surveillance of patients
with FAP with regard to the presence of desmoid
tumors, principally because there are no real pre-
ventive strategies. Thus, some advocate no surveil-
lance at all. However, because the mortality due to
polyposis is decreasing and morbidity and mortality
from desmoid tumors is increasing, it seems reason-
able to look for intra-abdominally located desmoid
tumors using CT or MRI scan,
95 especially in patients
with a gene mutation between codons 1,444 and 1,578
or in those with a family history of desmoids. Because
desmoids often arise as a consequence of tissue trau-
ma, a delay of surgery and the type of surgery should
be considered in patients at high risk of developing
desmoids, at least in those with a smaller number of
polyps or when the onset of colon malignancies is
expected to occur later in life. Mutation analysis may
be of help in such cases as an aid in decision mak-
ing.
96–99 Ileal pouch–anal anastomosis is advocated as
the appropriate type of surgery in FAP patients with a
positive family history of desmoids.
100
FAP, OSTEOMAS AND DENTAL
ABNORMALITIES
Epidemiology and Genetics
The prevalence of osteomas is about 20% in FAP
patients compared with 1–2% in the general popu-
lation. Mutations are found in codons 767 to 1,578.
Dental abnormalities occur frequently with an esti-
mated prevalence of 17%.
101 As with other manifes-
tations, osteomas and dental abnormalities may also
precede the actual development of colon polyps in
FAP patients.
102
Clinical Findings
Osteomas are benign bone growths most com-
monly found in the skull and mandible. However,
they may occur in any bone of the body.
103 Their size
ranges from less than a millimeter to several centi-
meters. They can give rise to cosmetic concerns.
The dentition during childhood can be disturbed by
thepresenceofsupernumeraryteeth,dentigerouscysts
and a phenomenon referred to as secondary retention
of teeth. Supernumerary teeth and dentigerous cysts
can obstruct normal teeth from erupting. This is often
an indication for surgical removal. Supernumerary
teeth are usually present before the age of 10 years.
The development of cysts can occur at any age. Den-
tigerous cysts are those that develop from the epithe-
lium of the enamel organ; therefore, the risk of
developing such a cyst is greatest when teeth are still
developing in the jaw. They can sometimes grow and
occupy more than a quarter of the mandible. Such
cysts lead to local destruction of the jaw and removal
can have profound consequences for the patient. The
phenomenon of secondary retention of teeth has also
been described in FAP patients. In such cases, erupted
teethareretainedatacertainpositioninthejaw,which
is usually caused by ankylosis. This results in a sub-
merged position of the involved tooth. It is not nec-
essarytotreatsuchteethwhentheydonotobstructthe
eruption of other teeth. When these teeth give prob-
lems, removal is usually the only option.
Considerations for Surveillance
A normal dentition is fully developed at 18 years of
age. Disclosure at anearly stage is therefore important
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removal. The literature on dental anomalies in FAP
patients is mainly restricted to a description of the
pathology,
104 and no surveillance recommendations
have been published. In comparable syndromes with a
high risk of developing cysts in the jaws, such as the
nevoid basal cell carcinoma syndrome, it is recom-
mended that a routine panorex is made every 1–
2 years for early disclosure of cysts.
105 The incidence
of the development of dental anomalies in FAP is
clearly increased relative to that in normal individuals,
and treatment at a later age has been described as
complicated.
106 It is therefore recommended that in
the routine follow-up, a panorex is included at least
every 2 years in a developing child until the teeth have
erupted (* 18 years).
101 In this way, problems caused
by undetected dental abnormalities later in life can be
prevented.
FAP AND OTHER BENIGN MANIFESTATIONS
Epidermoid cysts, ﬁbromas and lipomas are all
considered (sub)cutaneous lesions and may cause
cosmetic problems. Cysts occasionally become in-
fected, necessitating operative removal. Nasopha-
ryngeal angioﬁbromas have been described in some
patients with FAP syndrome. They occur 25 times
more frequently in patients with FAP than in an age-
matched population.
107
Congenital hypertrophy of the retinal pigment
epithelium (CHRPE) is the most common extra-co-
lonic manifestation of FAP and an early marker for it.
Approximately 60% of patients with FAP have
CHRPE. Multiple or bilateral patches of these lesions
are highly speciﬁc (95%) for FAP syndrome.
108 It
appears as well-demarcated grey-brown to black
round or oval lesions in the retinae of affected indi-
viduals and is not known to cause any clinical prob-
lems. Mutations in the region between codons 543 and
1,309 in the APC gene are associated with a high risk
of CHRPE.
109 Ophthalmoscopic surveillance for
CHRPE is a direct, non-invasive and inexpensive test.
If the index case has CHRPE, then surveillance for
CHRPE has been successfully used as an early clinical
marker to detect affected family members.
110
CONCLUSION
FAP is due to a germline mutation in the APC
gene. The development of colorectal cancer stands
out as the most characteristic manifestation of this
disease. Prophylactic colectomy has improved the life
expectancy of patients, as a result of which the
prevalence of other manifestations has increased. In
appreciation of the development of various forms of
benign and malignant tumors, it seems more appro-
priate to speak of FAP syndrome. The diverse mul-
tisystem eﬀects of FAP syndrome manifest during
diﬀerent phases of life and in association with dif-
ferent mutations. Some tumors can present during
early childhood before the classical colonic polyps
cause problems, and this may be the ﬁrst clue that
FAP is present. Many FAP cases are due to sponta-
neous mutations, with no antecedent family history,
and many parents are poorly informed about their
own FAP and cannot be counted on to connect their
child’s disease (for instance a hepatoblastoma or a
brain tumor) with their own. Therefore, to optimize
health care for FAP families, the surgeon and the
gastroenterologist who are often the primary FAP
experts also have a key role as education providers.
SEARCH STRATEGY
We searched the PubMed database using the key-
words Familial Adenomatous Polyposis or Gardner
syndrome, combined with the terms molecular
genetics, thyroid carcinoma, hepatoblastoma, brain
tumor, pancreatic tumor, adrenal tumor, desmoid
tumor, osteoma, dental abnormalities or benign
manifestations. We focused mainly on manuscripts
published during the past 10 years, but have also
referenced key papers from before then. In addition,
relevant articles that were identiﬁed by papers found
in this search strategy have also been referenced.
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